Lynn C Hartmann
Overview
Explore the profile of Lynn C Hartmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
145
Citations
5763
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Degnim A, Ghosh K, Vierkant R, Winham S, Hoskin T, Carter J, et al.
JNCI Cancer Spectr
. 2025 Jan;
9(1).
PMID: 39786446
Background: Benign breast disease (BBD) increases breast cancer (BC) risk progressively for women diagnosed with nonproliferative change, proliferative disease without atypia (PDWA), and atypical hyperplasia (AH). Leveraging data from 18 ...
2.
Mariani A, Wang C, Oberg A, Riska S, Torres M, Kumka J, et al.
Gynecol Oncol
. 2019 Jun;
154(3):495-504.
PMID: 31204077
Objective: This study is designed to identify genes and pathways that could promote metastasis to the bowel in high-grade serous ovarian cancer (OC) and evaluate their associations with clinical outcomes....
3.
Yasir S, Nassar A, Jimenez R, Jenkins S, Hartmann L, Degnim A, et al.
Ann Diagn Pathol
. 2018 Jul;
35:85-91.
PMID: 30029048
Some fibroepithelial lesions (FEL) of the breast are difficult to classify as cellular fibroadenoma (CFA) or benign phyllodes tumor (BPT) due to overlapping histologic features. This indeterminate group is histologically...
4.
Frank R, Winham S, Vierkant R, Frost M, Radisky D, Ghosh K, et al.
Cancer
. 2018 Jun;
124(16):3319-3328.
PMID: 29932456
Background: More than 1.5 million women per year have a benign breast biopsy resulting in concern about their future breast cancer (BC) risk. This study examined the performance of 2...
5.
Degnim A, Winham S, Frank R, Pankratz V, Dupont W, Vierkant R, et al.
J Clin Oncol
. 2018 Apr;
36(18):1840-1846.
PMID: 29676945
Purpose Women with atypical hyperplasia (AH) on breast biopsy have an aggregate increased risk of breast cancer (BC), but existing risk prediction models do not provide accurate individualized estimates of...
6.
Ghosh K, Vierkant R, Frank R, Winham S, Visscher D, Pankratz V, et al.
Breast Cancer Res
. 2017 Dec;
19(1):134.
PMID: 29258587
Background: Over 40% of women undergoing breast screening have mammographically dense breasts. Elevated mammographic breast density (MBD) is an established breast cancer risk factor and is known to mask tumors...
7.
Wahner Hendrickson A, Menefee M, Hartmann L, Long H, Northfelt D, Reid J, et al.
Clin Cancer Res
. 2017 Nov;
24(4):744-752.
PMID: 29138343
To determine the dose limiting toxicities (DLT), maximum tolerated dose (MTD), and recommended phase II dose (RP2D) of veliparib in combination with weekly topotecan in patients with solid tumors. Correlative...
8.
Winham S, Mehner C, Heinzen E, Broderick B, Stallings-Mann M, Nassar A, et al.
Breast Cancer Res Treat
. 2017 Aug;
166(2):641-650.
PMID: 28798985
Purpose: Sclerosing adenosis (SA), found in ¼ of benign breast disease (BBD) biopsies, is a histological feature characterized by lobulocentric proliferation of acini and stromal fibrosis and confers a two-fold...
9.
Stallings-Mann M, Heinzen E, Vierkant R, Winham S, Hoskin T, Denison L, et al.
Breast Cancer Res Treat
. 2017 Jul;
166(1):133-143.
PMID: 28752190
Purpose: Breast terminal duct lobular units undergo two distinctive physiological processes of involution: age-related lobular involution (LI), which is gradual and associated with decreased breast cancer risk, and postlactational involution,...
10.
Visscher D, Frank R, Carter J, Vierkant R, Winham S, Heinzen E, et al.
J Natl Cancer Inst
. 2017 Apr;
109(10).
PMID: 28376198
Background: More than 1 million women per year in the United States with benign breast biopsies are known to be at elevated risk for breast cancer (BC), with risk stratified...